AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic DrugsCatherine Wilson(Discovery Centre), Jeff Settleman(Discovery Centre)Cancer ResearchAugust 15, 201410.1158/0008-5472.can-14-1009Cited by 145SaveCiteExport RISWatch citationsRelated PapersThe Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation|Cancer Research|2014|308Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition|Oncotarget|2014|142